RC 3095

Drug Profile

RC 3095

Alternative Names: D 21663; RC-3095

Latest Information Update: 12 Sep 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tulane University
  • Developer AEterna Zentaris Inc
  • Class Antineoplastics
  • Mechanism of Action Gastrin-releasing peptide inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Solid tumours

Most Recent Events

  • 04 Aug 2005 This compound is still in active development for Cancer
  • 01 Jun 2004 AEterna Laboratories is now called AEterna Zentaris
  • 11 Jul 2003 Phase-II clinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top